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Abstract: The glaucomatous disease is currently considered a disease involving ocular and visual brain
structures. This new approach to glaucoma introduces the possibility of inducing an improvement by means of
a pharmacological approach similar to that used in different degenerative brain disorders. In line with this
hypothesis, we studied the effects of oral (1600 mg/die, Cebroluxs, Tubilux Pharma, Pomezia, Rome, Italy) or
intramuscular (1000 mg/die, Cebrotons, Tubilux Pharma) cytidine-5u-diphosphocholine (citicoline) treatment
on retinal function and neural conduction in the visual pathways of glaucoma patients with moderate visual
defects. Improvement of retinal function (objectively evaluated by pattern electroretinogram recordings) and
of neural conduction along visual pathways (objectively evaluated by visual evoked potential recordings) were
observed in glaucoma patients after two 60-day periods of oral or intramuscular treatment with citicoline.
However, partial regression of this improvement was detected after two 120-day periods of washout. This
suggests that the beneﬁcial effects observed are in part treatment-dependent. The extension of citicoline
treatment up to a period of 8 years lead to the stabilization or improvement of the glaucomatous visual
dysfunction. These results suggest potential neuroprotective effects of citicoline in the glaucomatous disease.
Keywords: citicoline; glaucoma; visual evoked potentials; pattern electroretinogram; innermost retinal
layers; visual pathways; visual functionIntroduction
The glaucomatous disease open angle glaucoma
(OAG) is commonly characterized by the presence
of increased intraocular pressure (IOP), typical
optic nerve head cupping, and visual ﬁeld defects,Corresponding author. Tel.: +390685356727;
Fax: +390686216880; E-mail: vparisi@tin.it
DOI: 10.1016/S0079-6123(08)01137-0 541in particular, evaluated by Humphrey Field
Analyzer (HFA) (Graham et al., 1996).
HFA perimetry, however, does not selectively
reveal which structures contribute to the impair-
ment of the visual system observed in glaucoma.
Alternatively, electrophysiological methods may
allow us to explore the different structures that
contribute to visual function.
The function of retinal preganglionic elements can
be objectively evaluated by recording electroretino-
graphic signals evoked by ﬂash stimuli (ﬂash
542electroretinogram, ERG) (Armington, 1974). Studies
in animals (Maffei and Fiorentini, 1982) and humans
(Holder, 1997; Parisi et al., 1999d; Parisi, 2003)
suggest that the function of retinal ganglion cells
(RGCs) and their ﬁbers can be assessed by electro-
retinographic signal recordings evoked by pattern
stimuli (pattern ERG, PERG). The function of the
entire visual pathway can be assessed by recording
cortical potentials evoked by patterned stimuli (visual
evoked potentials, VEPs) (Celesia et al., 1993).
Several studies performed in groups of patients
with ocular hypertension without visual ﬁeld defects
(OHT patients) or in groups of patients with
glaucoma showed the presence of normal or impaired
ﬂash ERG responses (Gur et al., 1987; Vaegan et al.,
1995), impaired PERG (Porciatti et al., 1987;
Watanabe et al., 1989; Parisi, 1997, 2001; Parisi
et al., 1997, 1999c, 2001, 2006; Salgarello et al., 1999;
Bach, 2001; Garway-Heath et al., 2002; Ventura
et al., 2005), and VEP (Parisi and Bucci, 1992;
Greenstein et al., 1998; Martus et al., 1998; Klistorner
and Graham, 1999; Parisi, 1997, 2001; Horn et al.,
2002; Parisi et al., 1997, 1999c, 2001, 2006) responses
when compared to responses obtained in groups of
normal subjects.
The results provided by electrophysiological
studies suggest that the natural history of glaucoma
involves the early impairment of the innermost
retinal layers (which may precede the onset of visual
ﬁeld defects) (Parisi et al., 2006), which may be
followed by an impairment, due to transynaptic
degeneration, in postretinal visual pathways and in
particular at the level of the lateral geniculate nucleus
(LGN) (Chaturvedi et al., 1993; Weber et al., 2000;
Yucel et al., 2000, 2003; Gupta and Yucel, 2003).
These observations lead us to believe that the
glaucomatous disease must not be considered as a
disease exclusively involving ocular structures, but is
a pathology in which visual brain structures are also
compromised.
Thus, since 1996, we are paying our attention on
the possibility of inducing an improvement of
visual function using a pharmacological approach
similar to that used in different brain disorders
ascribed to vascular, traumatic, or degenerative
processes (Boismare et al., 1978; Serra et al., 1981;
Agnoli et al., 1985; Zappia et al., 1985; Kakihana
et al., 1988; Cacabelos et al., 1996).In particular, in our two previously published
studies, we observed that the glaucomatous visual
impairment may be improved by treatment with
nicergoline (Parisi et al., 1999a) or with cytidine-
5u-diphosphocholine (citicoline) (Parisi et al.,
1999b). Nevertheless, the beneﬁcial effects of
these treatments are treatment-dependent. In
particular, 45 and 300 days (respectively for
nicergoline and citicoline) (Parisi et al., 1999a,
b) after the end of the treatment, no differences
were detected with respect to pretreatment con-
ditions. When a second period of citicoline
treatment was performed, we observed that even
after a long period of washout (120 days), it is
possible to once again detect visual function
improvement, suggesting that repeated treatments
may inhibit the development of the visual
impairment (Parisi et al., 1999b).
In the above-mentioned study (Parisi et al.,
1999b), citicoline treatment was performed by
intramuscular injection. As this administration
route requires suitable paramedical abilities, it
could represent a real problem for patients’ self-
administration and thus patient compliance.
At present, citicoline is available as an oral
formulation. This can represent an advantage for
many patients whose visual dysfunction, as
observed in previously published studies, can
improve after citicoline treatment.
This chapter presents data regarding studies that
evaluated the effects of oral or intramuscular
treatment with citicoline on the function of the
retina and visual pathways. In these studies, the
effects of citicoline on visual ﬁeld sensitivity were
purposely not considered because any detectable
improvement could be ascribed to the associated
effects on consciousness level and attention (Zappia
et al., 1985).
In addition, this chapter discusses whether
citicoline effects may be considered as ‘‘neuropro-
tective’’, which is able to prevent the development
of the glaucomatous disease.Patients: selection and recruitment criteria
Seventy eyes of 60 patients (range: 38–62 years,
mean age 52.7775.28 years) affected by OAG
543with moderate visual ﬁeld defects [HFA with
mean deviation (MD) between 2 and 14 dB;
corrected pattern standard deviation (CPSD)
between +2 and +12dB] were studied. OAG
patients were selected from a very large population
(172 OAG patients) on the basis of the inclusion
criteria extensively reported in our previously
published study (Parisi et al., 2006).
Because it is known that PERG responses can be
modiﬁed by the pharmacological reduction of IOP
(Colotto et al., 1995; Ventura and Porciatti, 2005),
we only enrolled OHT and OAG patients with IOP
values less than 18mmHg on beta-blocker mono-
therapy maintained during the 8 months preceding
the electrophysiological evaluation.
All OAG patients were randomly divided on the
basis of age and visual ﬁeld defects into three
groups (see below):
– Group NT-OAG (not treated open-angle
glaucoma): 20 OAG patients (range: 39–61
years, mean age 51.6474.68 years, 20 eyes) in
which no additional pharmacological treat-
ment was performed.
– Group TI-OAG (glaucoma patients treated
with intramuscular citicoline): 20 OAG
patients (range: 41–62 years, mean age
52.5475.43 years, 20 eyes) treated with a
daily intramuscular dose of 1000mg citicoline
(Cebroton 1000s, Tubilux Pharma, Pomezia,
Rome, Italy).
– Group TO-OAG (glaucoma patients treated
with oral citicoline): 20 OAG patients (range:
38–60 years, mean age 50.8476.62 years, 20
eyes) treated with a daily oral dose of 1600mg
citicoline (Cebroluxs, Tubilux Pharma).
The research followed the tenets of the Declara-
tion of Helsinki. The protocol was approved by
the local Institutional Review Board (IRB). Upon
recruitment, each patient gave informed consent.Pharmacological treatment protocol
The pharmacological treatment was performed
according to the following schedule.
First period — A daily intramuscular dose of
1000mg citicoline or oral dose of 1600mgciticoline was prescribed according to the follow-
ing protocol:
– 0–60 days: First period of pharmacological
treatment with oral or intramuscular citico-
line.
– 61–180 days: First period of washout and
follow-up at the sixth month.
Second period — A daily intramuscular dose of
1000mg citicoline or oral dose of 1600mg citico-
line was prescribed according to the following
protocol:
– 181–240 days: Second period of pharmacolo-
gical treatment with oral or intramuscular
citicoline.
– 241–360 days: Second period of washout and
follow-up at the twelfth month.Methodology of visual function evaluation:
electrophysiological examinations
PERG and VEP recordings were performed using
the following methods (Parisi, 1997, 2001; Parisi
et al., 1997, 1999c, 2001, 2006).
Brieﬂy, subjects were seated in a semidark,
acoustically isolated room in front of the display
surrounded by a uniform ﬁeld of luminance of
5 cd/m2. Prior to the experiment, each subject was
adapted to the ambient room light for 10min and
pupil diameter was approximately 5mm. Mydria-
tic or miotic drugs were never used. Stimulation
was monocular after occlusion of the other eye.
Visual stimuli were checkerboard patterns (con-
trast 80%, mean luminance 110 cd/m2) generated
on a TV monitor and reversed in contrast at the
rate of 2 reversals per second; at the viewing
distance of 114 cm, the check edges subtended 15
minutes (15u) of visual angle. The monitor screen
subtended 181. PERG and VEP recordings were
performed with full correction of refraction at the
viewing distance. A small red ﬁxation target,
subtending a visual angle of approximately 0.5
degrees (estimated after taking into account
spectacle-corrected individual refractive errors)
was placed at the center of the pattern stimulus.
At every PERG and VEP examination, each
544patient positively reported that he/she could
clearly perceive the ﬁxation target. The refraction
of all subjects was corrected for viewing distance.
PERG recordings
The bioelectrical signal was recorded by a small
Ag/AgCl skin electrode placed over the lower
eyelid. PERGs were derived bipolarly between the
stimulated (active electrode) and the patched
(reference electrode) eye using a previously
described method (Fiorentini et al., 1981). As the
recording protocol was extensive, the use of skin
electrodes with interocular recording represented a
good compromise between signal-to-noise ratio
(SNR) and signal stability. The ground electrode
was in Fpz. Interelectrode resistance was lower
than 3000 ohms. The signal was ampliﬁed (gain
50,000), ﬁltered (band pass 1–30Hz), and averaged
with automatic rejection of artifacts (200 events
free from artifacts were averaged for every trial) by
BM 6000 (Biomedica Mangoni, Pisa, Italy).
Analysis time was 250ms. The transient PERG
response is characterized by a number of waves
with three subsequent peaks, of negative, positive,
negative polarity, respectively. In normal subjects,
these peaks have the following implicit times: 35,
50, and 95ms (N35, P50, N95).
VEP recordings
Cup-shaped electrodes of Ag/AgCl were ﬁxed with
collodion in the following positions: active electrode
in Oz, reference electrode in Fpz, and ground in the
left arm. Interelectrode resistance was kept below
3000ohms. The bioelectric signal was ampliﬁed
(gain 20,000), ﬁltered (band pass 1–100Hz), and
averaged (200 events free from artifacts were
averaged for every trial) by BM 6000. Analysis
time was 250ms. The transient VEP response is
characterized by a number of waves with three
subsequent peaks, of negative, positive, negative
polarity, respectively. In normal subjects, these
peaks have the following implicit times: 75, 100,
and 145 ms (N75, P100, N145).
During a recording session, simultaneous VEPs
and PERGs were recorded at least twice (2–6
times) and the resulting waveforms weresuperimposed to check the repeatability of the
results. All control, OHT, and OAG eyes under-
went at least two recording sessions, 1–7 days
apart, to determine test–retest variability.
In each subject or patient, the SNR of PERG
and VEP responses was assessed by measuring a
‘‘noise’’ response, while the subject ﬁxated at an
unmodulated ﬁeld of the same mean luminance as
the stimulus. At least two ‘‘noise’’ records of 200
events each were obtained and the resulting grand
average was considered for measurement. The
peak-to-peak amplitude of this ﬁnal waveform
(i.e., average of at least two replications) was
measured in a temporal window corresponding to
that at which the response component of interest
(i.e., VEP N75-P100, PERG P50-N95) was
expected to peak. SNRs for this component were
determined by dividing the peak amplitude of the
component by the noise in the corresponding
temporal window. An electroretinographic noise
o0.1 mV (mean: 0.085 mV, range: 0.065–0.095 mV,
resulting from the grand average of 400–1200
events) and an evoked potential noiseo0.15 mV
(mean: 0.093 mV, range: 0.072–0.112 mV, resulting
from the grand average of 400–1200 events) were
observed in all tested subjects. In all subjects and
patients, we accepted VEP and PERG signals with
an SNR W2.
Implicit time and peak amplitude of each wave
were measured directly on the displayed records by
means of a pair of cursors for all VEPs and
PERGs. Simultaneous recordings of VEPs and
PERGs allow us to derive Retinocortical Time
(RCT) as the difference between VEP P100 and
PERG P50 peak latencies (Celesia and Kaufmann,
1985).
At baseline, all OAG patients underwent at least
two simultaneous recordings of PERG and VEP
1–7 days apart to determine test–retest variability.
During the follow-up assessment (60, 180, 240, and
360 days), PERGs and VEPs were performed in
OAG patients at least three times and the resulting
waveforms were superimposed to check the
repeatability of the results. The recording with the
highest PERG P50-N95 amplitude was considered
in the statistical analysis (see below). During all
follow-up examinations, PERG and VEP record-
ings were performed in a condition of pupil
545diameter equal to that measured in baseline
conditions (see above).Statistic evaluation of electrophysiological results
Sample size estimates were obtained from pilot
evaluations performed in 20 eyes from 20 OAG
patients and 20 eyes from 20 control subjects,
other than those included in the current study.
Interindividual variability, expressed as data stan-
dard deviation (SD), was estimated for PERG
P50-N95 amplitude and VEP P100 implicit time
measurements. It was found that data SDs were
signiﬁcantly higher for patients when compared to
controls (about 35% vs. 15%). It was also
established that, assuming the above between-
subjects SD in the current study, sample sizes of
control subjects and patients belonging to OAG
group provided a power of 90%, at an
alpha ¼ 0.05, for detecting a between-group dif-
ference of 55% or greater in PERG P50-N95
amplitude and VEP P100 implicit time measure-
ments. These differences were preliminarily
observed by comparing OAG and control data
(see above). They were also expected to be
clinically meaningful when comparing results of
treated OAG eyes observed in baseline conditions
versus those observed at 60, 180, 240, and 360
days.
Test–retest data of PERG and VEP results were
expressed as the mean difference between two
recordings obtained in separate sessions plus/
minus the SD of this difference. Ninety-ﬁve
percent conﬁdence limits of test–retest variability
in normal subjects and patients were established
assuming a normal distribution.
The differences of PERG and VEP responses
between groups (NT-OAG, TO-OAG, and TI-OAG
eyes) were evaluated by one-way analysis of
variance (ANOVA). Changes in PERG and VEP
responses observed in NT-OAG, TO-OAG, and TI-
OAG groups with respect to baseline were evaluated
by one-way repeated measures ANOVA. The
differences observed in individual TO-OAG eyes
after observation or citicoline treatment with respect
to baseline values were calculated by performing a
logarithmic transformation to better approximate anormal distribution. In all analyses, a conservative
p value less than 0.01, to compensate for multi-
ple comparisons, was considered as statistically
signiﬁcant.Electrophysiological (PERG and VEP) responses in
OAG patients after the ﬁrst period of evaluation
Examples of simultaneous recordings of VEP and
PERG before and after treatment with oral
citicoline are displayed in Fig. 1. Individual
changes observed in TO-OAG eyes are shown in
Fig. 2. Mean values observed in NT-OAG,
TI-OAG, and TO-OAG eyes are presented in
Figs. 3 and 4.
A decrease in PERG P50 implicit time, VEP
P100 implicit time, and RCT, and an increase in
PERG P50-N95 and VEP N75-P100 amplitudes
(po0.01) were found in TO-OAG and TI-OAG
patients after 60 days of treatment (day 60) with
respect to baseline values. TO-OAG and TI-OAG
patients displayed shorter PERG P50 implicit
time, VEP P100 implicit time, and RCT, and
greater PERG and VEP amplitudes with respect to
NT-OAG patients (po0.01).
Increased PERG P50 implicit time, VEP P100
implicit time, and RCT, and decreased PERG P50-
N95 and VEP N75-P100 amplitudes were found at
day 180 with respect to values observed at 60 days.
PERG and VEP parameters observed were still
shorter (P50 implicit time, P100 implicit time,
RCT) and still greater (P50-N95 and N75-P100
amplitudes) with respect to those observed in
baseline conditions (po0.01) and with respect to
those observed in NT-OAG patients (po0.01).
No changes (pW0.01) in PERG and VEP
responses were observed in NT-OAG patients after
60 and 180 days with respect to baseline conditions.Electrophysiological (PERG and VEP) responses in
OAG patients after the second period of evaluation
A further decrease in PERG P50 implicit time,
VEP P100 implicit time, and RCT, and a further
increase in PERG P50-N95 and VEP N75-P100
amplitudes (po0.01) were observed in TO-OAG
Fig. 1. Examples of visual ﬁeld (Humphrey 30-2) and layouts of simultaneous visual evoked potentials (VEPs) and pattern
electroretinograms (PERGs) recorded in two patients affected by open-angle glaucoma treated with oral citicoline (TO-OAG#3,
TO-OAG#7). Electrophysiological examinations were assessed at baseline conditions and 60, 180, 240, and 360 days after medical
treatment with oral citicoline. Oral citicoline treatment was performed in two different 60-day periods (0–60 and 181–240 days), each
followed by a period of washout (61–180 and 241–360 days). TO-OAG patients showed a decrease in implicit times and an increase in
amplitude after the ﬁrst period of citicoline treatment (60 days) when compared to baseline conditions. At the end of the second period
of washout (360 days), one OAG patient (TO-OAG#3) showed electrophysiological and visual ﬁeld parameters similar to those
observed in baseline conditions, while in the other example (TO-OAG#7), the visual ﬁeld and electrophysiological improvements
observed after oral citicoline treatment remained stable even after the washout period.
546and TI-OAG patients, at day 240, with respect to
values observed at day 180. PERG and VEP
implicit times and RCT were still shorter and
PERG and VEP amplitudes were still greater when
compared to NT-OAG patients (po0.01). At day360, TO-OAG and TI-OAG patients showed an
increase in VEP and PERG implicit times and in
RCT, and a decrease in amplitudes with respect to
values observed at 240 days. Implicit time and
amplitude values were respectively still shorter and
Fig. 2. Individual changes in pattern electroretinogram (PERG), visual evoked potential (VEP) responses, and retinocortical time
(difference between VEP P100 and PERG P50 implicit times and RCT) observed in eyes affected by open-angle glaucoma treated with
oral citicoline (TO-OAG). Values refer to the difference observed after 60, 180, 240, and 360 days with respect to baseline conditions.
Medical treatment with citicoline was performed in TO-OAG eyes over a 60-day period followed by 120 days of washout. At day 180,
a second 60-day period of citicoline treatment followed by a second period of 180 days of washout was performed. Solid and dashed
lines refer respectively to the upper and lower 95% conﬁdence limit of the intraindividual variability resulting from test–retest analysis.
547still greater when compared to baselines (po0.01)
and when compared to NT-OAG patients
(po0.01).
No changes (pW0.01) in PERG and VEP
responses were observed in NT-OAG patients,
after 240 and 360 days, with respect to baseline
conditions.
Considering electrophysiological responses
observed after the two different periods of treatment
or washout, no signiﬁcant differences (pW0.05) were
found between TO-OAG and TI-OAG patients
when comparing VEP and PERG changes in implicit
times or amplitudes (see Fig. 4).Adverse side effects were not reported by any of
the patients enrolled in the study during the entire
period of treatment. Signiﬁcant changes in IOP
were not found in any of the subjects tested.
Effects of citicoline on retinal function in glaucoma
patients: neurophysiological implications
Oral or intramuscular treatment with citicoline
induces an improvement of retinal bioelectric
responses in our glaucomatous patients, as sug-
gested by the increase in amplitudes and short-
ening in implicit times of PERG recordings.
Fig. 3. Graphic representation of mean values of PERG P50 implicit time and P50-N95 amplitude, VEP P100 implicit time, and RCT
observed in patients affected by open-angle glaucoma without additional treatments (NT-OAG) and in patients with glaucoma treated
with oral (TO-OAG) or intramuscular (TI-OAG) citicoline. Solid lines indicate periods of medical treatment, while dashed lines
indicate periods of washout. Vertical lines represent one standard error of the mean. Statistical analysis (ANOVA) evaluating the
differences between TO-OAG and TI-OAG groups versus baseline conditions and with respect to NT-OAG group: po0.01; ypW0.01.
548In our studies we found that there were no
differences between oral and intramuscular treat-
ment with citicoline. The results obtained with
intramuscular treatment are consistent with those
observed in our previous study (Parisi et al., 1999b).
Although in this study, just as in our previous
study (Parisi et al., 1999b), our results clearly
suggest a positive effect of citicoline in improving
the retinal and postretinal glaucomatous dysfunc-
tion, the mechanism of action of citicoline in the
visual system is only in part understood.
Citicoline is an endogenous substance that acts
as intermediary in the synthesis of phosphatidyl-
choline (a major phospholipid in the neuronalmembrane) (Kennedy, 1957; Goracci et al., 1985;
Secades and Frontera, 1995; Weiss, 1995) through
the activation of the biosynthesis of structural
phospholipids in neuronal membranes. Citicoline
increases the metabolism of cerebral structures
(Secades and Frontera, 1995) and inhibits phos-
pholipid degradation (Weiss, 1995). It may there-
fore have potential neuroprotective and
neuromodulator roles as demonstrated in condi-
tions of cerebral hypoxia and ischemia (Secades
and Frontera, 1995; Weiss, 1995) and by the
evidence that it induces an increase in the levels of
different neurotransmitters and neuromodulators,
including noradrenaline, in the central nervous
Fig. 4. Bar graphs of the mean differences observed after oral or intramuscular citicoline treatment (60 and 240 days) or after washout
(180 and 360 days) with respect to baseline conditions. Means refer to changes in PERG P50 implicit time and P50-N95 amplitude,
VEP P100 implicit time, and RCT observed in patients affected by open-angle glaucoma treated with oral (TO-OAG) or intramuscular
(TI-OAG) citicoline. Vertical lines represent one standard deviation of the mean. The p value refers to a statistical analysis (ANOVA)
evaluating differences between TI-OAG and TO-OAG groups.
549system. In addition, several studies suggest that
citicoline successfully increases the level of con-
sciousness in different brain disorders ascribed to
vascular, traumatic, or degenerative processes
(Boismare et al., 1978; Serra et al., 1981; Agnoli
et al., 1985; Zappia et al., 1985; Kakihana et al.,
1988; Cacabelos et al., 1996).
Previous studies report that treatment with
citicoline may induce an improvement of the
glaucomatous visual ﬁeld defects (Pecori-Giraldi
et al., 1989; Virno et al., 2000). In our study, the
effects of citicoline on visual ﬁeld sensitivity were
purposely not considered because any detectable
improvement could be ascribed to the associatedeffects on consciousness level and attention
(Boismare et al., 1978; Serra et al., 1981; Agnoli
et al., 1985; Zappia et al., 1985; Kakihana et al.,
1988; Cacabelos et al., 1996).
A dopaminergic-like activity of citicoline may
also be involved in the improvement of PERG
responses after oral treatment; in fact, levodopa
was found to increase retinal function in humans
treated with this substance (Gottlob et al., 1989),
and our results could therefore be explained by a
similar neuromodulator activity.
In our study, we did not perform any morpholo-
gical examination, and thus, although our results
indicate that oral citicoline improves bioelectrical
550retinal activity, we were not able to demonstrate
whether there were other effects on retinal ﬁbers (i.e.,
an increase in retinal nerve ﬁber layer thickness).Effects of citicoline on neural conduction along the
visual pathways in glaucoma patients:
neurophysiological implications
Oral or intramuscular treatment with citicoline
induced an improvement of visual cortical bio-
electric responses (VEPs with increased amplitudes
and shortened times to peak) and an improvement
of the index of neural conduction in postretinal
visual pathways (reduced RCT) in our glaucoma-
tous patients. This is in agreement with a similar
previous study (Rejdak et al., 2003).
VEP abnormalities observed in patients with
glaucoma have recently been ascribed to impaired
neural conduction along postretinal visual path-
ways related to a dysfunction of the innermost
retinal layers (ganglion cells and their ﬁbers) (Parisi,
2001). An independent effect on neural conduction
in postretinal visual pathways or in visual cortical
cells could also be hypothesized in order to explain
the inﬂuence of citicoline in VEP responses.
The effects of citicoline in the neural visual
system were revealed by the improvement of visual
acuity (Campos et al., 1995; Porciatti et al., 1998),
VEP responses, and contrast sensitivity (Porciatti
et al., 1998) in amblyopic subjects after treatment
with this substance. Because similar results were
obtained in amblyopic subjects after treatment
with levodopa (Gottlob and Stangler-Zuschrott,
1990; Gottlob et al., 1992; Leguire et al., 1993) and
studies performed in patients with Parkinson’s
disease recommended the use of citicoline as a
complement to levodopa therapy (Birbamer et al.,
1990), a dopaminergic-like activity could once
again be suggested to explain VEP and RCT
results after treatment with citicoline.
Because there are no clear or conclusive experi-
mental or published data to support the hypothesis
of an independent effect on neural conduction in
postretinal visual pathways, the changes in neural
conduction along the visual pathways following
citicoline treatment could be dependent on the
reduced dysfunction of the innermost retinal layers.Possibility of neuroprotective role of citicoline in
glaucoma patients
Our results advocate an interesting question: can
oral or intramuscular citicoline effects be consid-
ered as ‘‘neuroprotective,’’ preventing the deve-
lopment of the glaucomatous disease?
For citicoline effects to be considered ‘‘neuro-
protective,’’ glaucomatous visual defects should
undergo stabilization or improvement long after
treatment termination.
When considering that after the ﬁrst period of
washout there were no differences with respect to
pretreatment conditions, this leads to the conclu-
sion that one cycle of treatment with citicoline is
not sufﬁcient to induce changes in the natural
history of glaucoma. On the other hand, we
observed that the second treatment period with
oral citicoline was able to induce an improvement,
which persisted after 120 days of washout.
These observations suggest that the improve-
ment in retinal function and postretinal neural
conduction along the visual pathways could be
considered as ‘‘treatment-dependent.’’
The results obtained in our ﬁrst study (Parisi et
al., 1999b) suggested us to perform in a restrict
cohort of selected patients (12 OAG patients only)
a series of 60-day periods of treatment each
followed by 120 days of washout during a total
period of 8 years (Parisi, 2005). This study showed
that after 8 years, glaucomatous patients subjected
to citicoline treatment displayed a stable or
improved electrophysiological and visual ﬁeld
impairment with respect to pretreatment condi-
tions (8 years before), while in similar glaucoma-
tous patients not subjected to citicoline treatment,
there was a worsening of the electrophysiological
and visual ﬁeld impairment with respect to
pretreatment conditions (8 years before). The
results of this study are summarized in Fig. 5.
Indeed, the data observed in our OAG patients
treated with beta-blockers plus several periods of
treatment with intramuscular citicoline with
respect to those found in OAG patients treated
with beta-blockers only may suggest the potential
use of citicoline in order to obtain the stabilization
or improvement of the glaucomatous visual
dysfunction.
Fig. 5. Graphic representation of mean values of PERG P50 implicit time, PERG P50-N95 amplitude, VEP P100 implicit time,
and retinocortical time (difference between VEP P100 and PERG P50 implicit times, an electrophysiological index of neural
conduction along postretinal visual pathways) observed in glaucoma patients at baseline conditions and without additional
treatment (hollow bar) or treated with intramuscular citicoline (solid bar). Medical treatment with citicoline was performed
over several 2-month periods followed by several 4-month periods of washout during an entire period of 96 months. The
solid line within solid bars indicates periods of treatment. The absence of a line within a solid bar indicates washout periods.
Vertical lines represent one standard error of the mean. We concentrated on the long-term effects of citicoline treatment
by comparing the differences observed at the end of each period of washout with respect to baseline conditions
through ANOVA. po0.01 versus baseline and untreated glaucoma patients. Adapted with permission from Parisi, 2005
(Figs. 2–5, pp. 98–99).
551These observations suggest that citicoline could
be considered a neuroprotective drug. Our study
showed that the neuroprotective effects of citico-
line may be achieved in a restricted cohort of
patients (see inclusion criteria, Parisi et al., 2006)
and must be considered ‘‘treatment-dependent,’’
leading to the possibility that repeated treatments
may determine possible neuroprotective effects.
In agreement with the reported observations of
similar studies (Kennedy, 1957; Campos et al., 1995;
Secades and Frontera, 1995; Weiss, 1995; Porciattiet al., 1998; Parisi et al., 1999b; Parisi, 2005), an
important aspect of this study is the lack of adverse
pharmacological side effects in all participating
subjects, even after long-term administration of
the drug.Conclusive remarks
The results provided by our studies suggest that
oral and intramuscular citicoline treatment
552signiﬁcantly improves retinal and cortical
responses in glaucoma patients. This indicates the
potential use of this substance in the medical
treatment of glaucoma, as a complement to
hypotensive therapy, with a possible direct neuro-
protective effect.Abbreviations
CPSD Corrected Pattern Standard
Deviation
ERG electroretinogram
HFA Humphrey Field Analyzer
IOP intraocular pressure
IRB Institutional Review Board
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MD mean deviation
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